Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

3.170 +0.420 (+15.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
InMed Pharmaceuticals Expanding Portfolio In Rare Cannabinoid Market
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
InMed Pharmaceuticals' Issues Annual Shareholder Letter
InMed Pharmaceuticals (NASDAQ: 
Via Benzinga
InMed's Evolution To Commercial Sales Featured In Research Report
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
InMed Names BayMedica VP Of Sales, Releases Q2 2022 Report
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... 
Via Benzinga
InMed Positioned To Offer Rare Cannabinoid Manufacturing Technologies
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
InMed Pharmaceuticals To Release Q2 Financial Report, Update
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... 
Via Benzinga
InMed Pharmaceuticals Strengthens Leading Role In Rare Cannabinoid Market
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cannabicitran is the first of four new rare cannabinoids InMed... 
Via Benzinga
InMed Pharmaceuticals Defining Value Of Rare Cannabinoids In Pharma Space
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
InMed Pharmaceuticals Expands Rare Cannabinoid Product Portfolio to Launch CBT
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... 
Via Benzinga
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste... 
Via Benzinga
InMed Pharmaceuticals to Present at Tribe Public's Webinar Event
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and... 
Via Benzinga
InMed Pharmaceuticals Announces Publication of Article on CBN as Possible Glaucoma Treatment
InMed Pharmaceuticals (NASDAQ: 
Via Benzinga
InMed Pharmaceuticals' Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following... 
Via Benzinga
InMed Pharmaceuticals Targeting Potential Therapeutics Addressing Unmet Needs
InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio... 
Via Benzinga
Topics Intellectual Property
InMed Pharmaceuticals Releases Q1 2022 Financial Results, Business Update
InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE: 
Via Benzinga
InMed Pharmaceuticals Announces Participation in Upcoming Cannabis Conference
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, will be participating in the 4th annual Cowen Cannabis... 
Via Benzinga
Topics Cannabis
54 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company... 
Via Benzinga
Welcome to the Party $INM! Competition or Compliment to $SNDL? — Cannabis Daily November 18, 2021
The Best Daily Overview Of The Cannabis Space South Dakota lawmakers recommend bill to legalize marijuana. New York ban... 
Via Benzinga
Topics Cannabis
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Sono Group N.V. (NASDAQ: SEV) rose 33% to $50.80 in pre-market trading. Sono Group shares climbed 155% on Wednesday after the company priced its IPO at $15 per share.... 
Via Benzinga
Topics Initial Public Offering
InMed Pharmaceuticals Working to Address Rare Cannabinoid Opportunities
InMed Pharmaceuticals (NASDAQ: 
Via Benzinga
InMed Pharmaceuticals Files Patent Application for Treatment of Neurodegenerative Diseases with Rare Cannabinoid
InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabi... 
Via Benzinga
Topics Intellectual Property
InMed Pharmaceuticals Inc. Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development, and commercialization of rare cannabinoids, today announced its filing of an international patent... 
Via Benzinga
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities
Special purpose acquisition company Soaring Eagle Acquisition Corp. combined with Ginkgo Bioworks to form publicly-listed Ginkgo Bioworks Holdings Inc., in what is the largest-... 
Via Benzinga
Topics Initial Public Offering
55 Biggest Movers From Friday
Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World... 
Via Benzinga
35 Stocks Moving In Friday's Mid-Day Session
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition as traders circulated... 
Via Benzinga
26 Stocks Moving in Friday's Pre-Market Session
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 300% to $6.10 in pre-market trading. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.